Yin Yin, Zhu Xu, Huang Shanshan, Zheng Jiawei, Zhang Mengyun, Kong Wencui, Chen Qun, Zhang Yan, Chen Xiong, Lin Kerong, Ouyang Xuenong
1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University, Fuzhou, China.
2 Department of Hepatobiliary Surgery, Fuzhou Dongfang Hospital, Xiamen University, Fuzhou, China.
Tumour Biol. 2017 Jun;39(6):1010428317699131. doi: 10.1177/1010428317699131.
The limited efficacy of conventional therapies for pancreatic ductal adenocarcinoma has led to the growing interest for identifying potential antigenic targets for immunotherapy. Placenta-specific 1 (PLAC1) is a new member of cancer-testis antigens with restricted expression in normal tissues. Ectopic activation of PLAC1 has been found in different types of cancers, but its role in pancreatic ductal adenocarcinoma remains unknown. This study evaluated the protein expression of PLAC1 and its clinical significance in pancreatic ductal adenocarcinoma. We examined PLAC1 expression in 93 pancreatic ductal adenocarcinoma samples by immunohistochemistry. The expression of PLAC1 was detected in 41 (44.1%) patients. Among patients' clinicopathological characteristics, PLAC1 expression was only significantly correlated with tumor differentiation (p = 0.028). Univariate analysis revealed that PLAC1 expression (p = 0.016) and tumor differentiation (p = 0.003) were significantly correlated with poor survival in the whole cohort. Subgroup analysis showed that PLAC1 expression was an independent prognostic biomarker in the perineural invasion positive subgroup (p < 0.05). This study demonstrated that the protein expression of PLAC1 was significantly associated with decreased overall survival in patients with pancreatic ductal adenocarcinoma, indicating that it was a valuable prognostic marker for pancreatic ductal adenocarcinoma and might be a potential target for immunotherapy.
传统疗法对胰腺导管腺癌的疗效有限，这使得人们越来越有兴趣寻找免疫治疗的潜在抗原靶点。胎盘特异性1（PLAC1）是癌胚抗原的一个新成员，在正常组织中表达受限。已发现在不同类型的癌症中PLAC1存在异位激活，但其在胰腺导管腺癌中的作用尚不清楚。本研究评估了PLAC1在胰腺导管腺癌中的蛋白表达及其临床意义。我们通过免疫组织化学检测了93例胰腺导管腺癌样本中PLAC1的表达。41例（44.1%）患者检测到PLAC1表达。在患者的临床病理特征中，PLAC1表达仅与肿瘤分化显著相关（p = 0.028）。单因素分析显示，在整个队列中，PLAC1表达（p = 0.016）和肿瘤分化（p = 0.003）与不良生存显著相关。亚组分析表明，在神经周围浸润阳性亚组中，PLAC1表达是一个独立的预后生物标志物（p < 0.05）。本研究表明，PLAC1的蛋白表达与胰腺导管腺癌患者的总生存期降低显著相关，表明它是胰腺导管腺癌的一个有价值的预后标志物，可能是免疫治疗的一个潜在靶点。
